Literature DB >> 2171796

Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline.

J P Eder1, B A Teicher, S A Holden, L Senator, K N Cathcart, L E Schnipper.   

Abstract

Four drugs known to interact with topoisomerase II were assessed for their ability to enhance the cytotoxicity of cis-diamminedichloroplatinum(II) (CDDP) in Chinese hamster ovary (CHO) cell lines sensitive and resistant to VM-26. The combination treatments were analyzed by isobologram methodology. On 24 h exposure, there was no significant difference in the cytotoxicity of novobiocin or ciprofloxacin toward either cell line. The resistant cells were approximately 9-fold more resistant to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and approximately 170-fold more resistant to etoposide after a 24-h exposure. The combination of novobiocin and cisplatin produced greater than additive cell kill over the entire dose range of cisplatin tested in both cell lines. m-AMSA and CDDP produced cell kill that fell within the envelope of additivity. Etoposide and CDDP resulted in cytotoxicity that was slightly greater than additive at low CDDP concentrations and additive at the highest concentration of CDDP tested in the parental cell line and was slightly greater than additive in the resistant cell line. Ciprofloxacin and CDDP, like novobiocin, resulted in greater than additive cell kill in both cell lines. The enhancement of CDDP cytotoxicity by novobiocin that was seen in exponentially growing cells was lost in stationary-phase cultures. In these studies, novobiocin and, to a lesser degree, ciprofloxacin produced greater than additive cell kill in combination with CDDP in parental and epipodophyllotoxin-resistant CHO cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171796     DOI: 10.1007/BF02994093

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

1.  Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line.

Authors:  D M Sullivan; M D Latham; T C Rowe; W E Ross
Journal:  Biochemistry       Date:  1989-06-27       Impact factor: 3.162

Review 2.  Recent studies of DNA topoisomerases.

Authors:  J C Wang
Journal:  Biochim Biophys Acta       Date:  1987-06-06

Review 3.  Inhibitors of DNA topoisomerases.

Authors:  K Drlica; R J Franco
Journal:  Biochemistry       Date:  1988-04-05       Impact factor: 3.162

4.  Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.

Authors:  R S Gupta
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

5.  A common mechanism for repair of O6-methylguanine and O6-ethylguanine in DNA.

Authors:  B Sedgwick; T Lindahl
Journal:  J Mol Biol       Date:  1982-01-05       Impact factor: 5.469

6.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity.

Authors:  G G Steel; M J Peckham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-01       Impact factor: 7.038

7.  Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.

Authors:  J P Eder; B A Teicher; S A Holden; K N Cathcart; L E Schnipper
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

8.  Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target.

Authors:  B Glisson; R Gupta; P Hodges; W Ross
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

9.  Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity.

Authors:  B Glisson; R Gupta; S Smallwood-Kentro; W Ross
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

10.  Dependence of mammalian DNA synthesis on DNA supercoiling. III. Characterization of the inhibition of replicative and repair-type DNA synthesis by novobiocin and nalidixic acid.

Authors:  M R Mattern; D A Scudiero
Journal:  Biochim Biophys Acta       Date:  1981-04-27
View more
  5 in total

1.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.

Authors:  J Walewski; J Romejko-Jarosińska; J Zwoliński; S Falkowski; P Siedlecki
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

3.  Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.

Authors:  B A Teicher; S A Holden; V Khandakar; T S Herman
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.

Authors:  Lisa M McGregor; Sheri L Spunt; Victor M Santana; Clinton F Stewart; Deborah A Ward; Amy Watkins; Fred H Laningham; Percy Ivy; Wayne L Furman; Maryam Fouladi
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

Review 5.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.